Ascendis Pharma

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

AstraZeneca's $800M rare disease bet hits primary phase 3 goal

The update keeps eneboparatide on track, but the lack of data leaves questions about its positioning versus Ascendis Pharma’s Yorvipath unanswered.
Nick Paul Taylor Mar 17, 2025 7:25am
Graphic of two hands shaking under a red and purple light

In $285M deal, Novo taps Ascendis to help create monthly GLP-1

Nov 4, 2024 8:43am
Graphic image of an arrow nailing the bullseye of a target

Ascendis' dwarfism drug hits in phase 3, threatens BioMarin

Sep 17, 2024 9:36am
very busy graphic of scientists working on an eye with one standing on a ladder preparing drops another set to apply a cont

Eyconis launches with $150M and Ascendis' eye disease meds

Jan 29, 2024 11:03am
Photo of two hands shaking

Ascendis sells Japan rights to Skytrofa, 2 other drugs for $70M

Nov 29, 2023 8:25am
Stop sign

FDA unexpectedly halts Ascendis' drug review

Apr 3, 2023 10:22am